Identification of novel multitargeted PPARα/γ/δ pan agonists by core hopping of rosiglitazone

The thiazolidinedione class peroxisome proliferator-activated receptor gamma (PPARγ) agonists are restricted in clinical use as antidiabetic agents because of side effects such as edema, weight gain, and heart failure. The single and selective agonism of PPARγ is the main cause of these side effects...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Xue-Jiao, Zhang, Jun, Wang, Shu-Qing, Xu, Wei-Ren, Cheng, Xian-Chao, Wang, Run-Ling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4232041/
https://www.ncbi.nlm.nih.gov/pubmed/25422585
http://dx.doi.org/10.2147/DDDT.S70383

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4232041/
https://www.ncbi.nlm.nih.gov/pubmed/25422585
http://dx.doi.org/10.2147/DDDT.S70383

Ejemplares similares